Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02019264 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
A Phase 4 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 4
- Development phase
- 14,673
- Enrollment target
NCT02019264: Completed Phase 4 study, sponsored by Eisai.
NCT02019264 is a Phase 4 study that has completed, run by Eisai. The registered enrollment target is 14,673 participants, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (2738% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02019264, a Phase 4 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14,673 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
Primary Outcome
The MACE events involved myocardial infarction (MI), stroke, or cardiovascular (CV) death. The outcome data was assessed using Kaplan-Meier estimate and Greenwood Formula.
Interventions
- DRUG Placebo
- DRUG Lorcaserin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,673 participants |
| Start Date | 2014-01-24 |
| Est. Completion | 2018-05-14 |
| Phase | Phase 4 |
What the finished NCT02019264 record still lists
NCT02019264 is an interventional study that assigns participants to a tested intervention. Its 14,673 participants enrollment target places it among the larger protocols in the corpus, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (2738% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02019264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02019264 about?
NCT02019264 is a clinical study titled "A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors". This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
What is the current status of trial NCT02019264?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14,673 participants. The study started on 2014-01-24. Estimated completion is 2018-05-14.
What interventions are being tested in trial NCT02019264?
The interventions under investigation include: Placebo (DRUG), Lorcaserin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02019264?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02019264's enrollment target sits among peer trials
14,673 7th of 2000 higher than 1,994 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- NCT06849869 · 14,820 participants · NA
Collaborative Care Model for Perinatal Wellness Support Services - Population-Level Equity-Centered Systems Change
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI